Financial Performance - The company's revenue for Q3 2022 was ¥326,173,926.53, a decrease of 3.25% compared to the same period last year[6]. - Net profit attributable to shareholders was ¥64,183,017.81, down 24.93% year-on-year[6]. - The basic earnings per share for Q3 2022 was ¥0.0892, reflecting a decline of 24.53% compared to the previous year[6]. - Total operating revenue for Q3 2022 was ¥928.39 million, a decrease of 4.54% from ¥972.79 million in Q3 2021[38]. - Net profit for Q3 2022 was ¥198.37 million, a decline of 6.15% compared to ¥211.42 million in Q3 2021[40]. - Operating profit for the period was ¥223.52 million, down 6.79% from ¥239.89 million in the same period last year[38]. - The company’s total profit for the period was ¥228.30 million, a decrease of 5.12% from ¥240.45 million in Q3 2021[40]. Cash Flow - The company reported a decrease in cash flow from operating activities by 9.39% year-to-date, totaling ¥244,700,394.94[6]. - The net cash flow from operating activities for the period was 24,470.04 million RMB, a decrease of 2,535.92 million RMB or 9.39% compared to the same period last year, primarily due to reduced sales revenue and collection of payments influenced by national medical device procurement policies[24]. - The net cash flow from investing activities was -11,419.91 million RMB, a decrease of 712.21 million RMB or 6.65% year-on-year, mainly due to a reduction in cash received from investment income and the disposal of fixed assets[25]. - The net cash flow from financing activities was -20,282.17 million RMB, a decrease of 6,306.53 million RMB or 45.13% compared to the previous year, primarily due to a decrease in cash received from borrowings[26]. - Total cash inflow from operating activities was 109,324.37 million RMB, down 10.82% from 122,586.48 million RMB in the previous year[23]. - Total cash outflow from operating activities was 84,854.33 million RMB, a decrease of 11.22% from 95,580.52 million RMB in the previous year[23]. - The company reported a net cash outflow from investing activities of ¥114.20 million, compared to a net outflow of ¥107.08 million in the previous year[43]. - The net cash flow from financing activities was -¥202,821,766.13, compared to -¥139,756,348.87 in the previous year, indicating a decline of approximately 45%[44]. - The cash flow from operating activities showed a significant outflow, with total cash outflow from financing activities amounting to ¥335,967,239.35, compared to ¥413,299,558.87 in the previous year[44]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,586,879,579.52, an increase of 2.21% from the end of the previous year[6]. - The company reported a total asset of CNY 3,586,879,579.52 as of September 30, 2022, an increase from CNY 3,509,475,704.32 at the beginning of the year[36]. - The total liabilities decreased to CNY 543,611,351.86 from CNY 731,099,383.73, a reduction of about 25.7%[37]. - The company's equity attributable to shareholders increased to CNY 2,969,743,445.01 from CNY 2,733,520,373.23, reflecting an increase of approximately 8.6%[37]. - The company’s total equity attributable to shareholders increased by 8.64% to ¥2,969,743,445.01 compared to the previous year[6]. Operational Changes - The company is actively communicating with distributors to assess the impact of centralized procurement policies on its existing distribution system[34]. - The centralized procurement for orthopedic spinal products was officially launched on July 11, 2022, with 14 product system categories established for procurement[33]. - The company plans to complete the assessment of the impact of centralized procurement policies on its financial data by the fourth quarter of 2022[34]. - The company is adjusting its operational strategies in response to the significant price reductions resulting from centralized procurement policies[34]. Other Income and Expenses - The company reported a 37.49% decrease in other income year-to-date, totaling ¥1,505.58 million[19]. - The company experienced a significant increase in other comprehensive income, which rose by 182.96% to ¥3,398.23 million, attributed to foreign exchange fluctuations[16]. - Other comprehensive income after tax was ¥74.95 million, compared to a loss of ¥3.87 million in the same period last year[40]. Inventory and Receivables - The company's cash and cash equivalents decreased to CNY 671,652,932.39 from CNY 729,026,805.82 at the start of the year, reflecting a decline of approximately 7.5%[36]. - The accounts receivable decreased to CNY 421,340,591.73 from CNY 453,914,327.85, indicating a reduction of about 7.2%[36]. - The company's inventory increased to CNY 317,535,559.84 from CNY 293,600,675.89, representing an increase of approximately 8.1%[36].

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥602.21 million, a decrease of 5.26% compared to ¥635.67 million in the same period last year[19]. - The net profit attributable to shareholders increased by 16.65% to approximately ¥132.63 million, up from ¥113.70 million in the previous year[19]. - The net profit after deducting non-recurring gains and losses rose by 21.11% to approximately ¥126.01 million, compared to ¥104.05 million in the same period last year[19]. - Basic earnings per share rose by 17.10% to ¥0.1842, compared to ¥0.1573 in the same period last year[19]. - The company's operating revenue for the reporting period was ¥602,212,936.76, a decrease of 5.26% compared to ¥635,674,828.80 in the same period last year, primarily due to the impact of the COVID-19 pandemic in the Shanghai area and a significant reduction in medical disinfection service revenue and trade business income[54]. - The company reported a total profit of CNY 150.83 million, a rise of 11.9% compared to CNY 135.21 million in the first half of 2021[182]. - The net profit margin for the period was approximately 10%, showcasing effective cost management strategies[196]. Cash Flow and Investments - The net cash flow from operating activities increased by 26.30% to approximately ¥137.78 million, compared to ¥109.08 million in the previous year[19]. - The net cash flow from investing activities decreased by 24.71% to -¥83.99 million, mainly due to a reduction in cash paid for fixed assets and other investments by ¥36.88 million[55]. - The net cash flow from financing activities increased by 29.97% to -¥61.82 million, attributed to a decrease in cash paid for debt repayment by ¥76.21 million[56]. - The total cash and cash equivalents at the end of the period stood at CNY 727,740,494.95, compared to CNY 647,019,143.43 at the end of the first half of 2021, reflecting an increase of 12.5%[190]. - The company reported a net increase in cash and cash equivalents of CNY 47,340,036.19 for the first half of 2022, compared to an increase of CNY 37,389,843.88 in the same period of 2021[193]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥3.61 billion, an increase of 2.88% from ¥3.51 billion at the end of the previous year[19]. - The total liabilities at the end of the reporting period were 3.8 billion, which is a 4.4% increase year-over-year[200]. - Cash and cash equivalents at the end of the reporting period amounted to ¥727,740,494, accounting for 20.16% of total assets, a decrease of 0.61% compared to the previous year[60]. - The company's long-term equity investments decreased to CNY 197,029,031.50 from CNY 201,335,495.25, a decline of approximately 2.13%[175]. Research and Development - Research and development expenses increased by 29.76% to ¥34,186,878.39 from ¥26,345,825.88, reflecting a commitment to innovation and product development[54]. - The company aims to increase its R&D investment by 15% in the upcoming fiscal year to drive innovation[197]. - The company is actively pursuing market expansion in regions such as Egypt, the Philippines, and Belarus for its new product lines[51]. - The company has ongoing research and development efforts in new medical technologies and products[69]. Market Strategy and Expansion - The company has successfully expanded its product line from a single spinal product to a comprehensive range of orthopedic high-value consumables, including trauma, spine, and minimally invasive joint products[27]. - Following the acquisition of Aideer, the company optimized and integrated the orthopedic product lines and sales channels, enhancing its core competitiveness and ensuring sustainable growth[31]. - The company aims to focus on the development of minimally invasive orthopedic products, particularly through its dual-brand strategy with Aideer[27]. - The company is exploring potential mergers and acquisitions to accelerate growth and market penetration[197]. - The company is focused on expanding innovative minimally invasive products across multiple departments in the future[47]. Quality Control and Compliance - The company emphasizes strict quality control as a competitive advantage, investing significant resources in quality management and training[46]. - The company adheres to national regulations in establishing a complete quality system, ensuring compliance in all operational stages[46]. - The company emphasizes product quality control and has not faced any product liability claims or related legal issues to date[95]. Shareholder and Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[4]. - The company held its first temporary shareholders' meeting on February 22, 2022, with an investor participation rate of 17.93%[113]. - The annual shareholders' meeting for 2021 was held on June 8, 2022, with a participation rate of 19.72%[113]. - The company has implemented a management incentive plan that includes restricted stock awards[157]. Social Responsibility - The company emphasizes its commitment to social responsibility and aims to contribute to public health initiatives[123]. - The company donated medical equipment worth over 7 million RMB to the Bethune Foundation to support flood relief efforts in Henan Province[124]. - The company, along with its subsidiaries, raised and donated various anti-epidemic supplies valued at hundreds of thousands of RMB to support frontline workers in Shanghai during the COVID-19 outbreak[125].

Financial Performance - The company's revenue for Q1 2022 was CNY 317,546,846.50, representing a 3.89% increase compared to CNY 305,647,901.76 in the same period last year[5]. - Net profit attributable to shareholders was CNY 75,490,587.03, a significant increase of 38.13% from CNY 54,650,621.97 year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 72,955,002.86, up 41.50% from CNY 51,557,080.92 in the previous year[5]. - Net profit for Q1 2022 was CNY 76,423,135.11, up 40.9% from CNY 54,226,373.92 in Q1 2021[34]. - Earnings per share (EPS) for Q1 2022 was CNY 0.1048, compared to CNY 0.0756 in the previous year, reflecting a growth of 38.4%[35]. - The company reported a total comprehensive income of CNY 73,320,376.69, up from CNY 58,501,314.00 in the same period last year[35]. Cash Flow - The net cash flow from operating activities reached CNY 62,035,512.25, an increase of 38.00% compared to CNY 44,952,128.00 in the same quarter last year[5]. - Cash generated from operating activities was CNY 348,557,949.37, compared to CNY 358,801,576.34 in the previous period[37]. - The total cash outflow from operating activities was ¥293,905,340.25, compared to ¥326,748,236.35 in the previous year, indicating a reduction of approximately 10.0%[38]. - The net cash flow from investment activities was -¥90,734,554.59, a significant decline from -¥3,385,125.40 in Q1 2021[38]. - Cash inflow from financing activities totaled ¥19,376,473.22, down from ¥55,607,316.00 in the same period last year, reflecting a decrease of approximately 65.2%[39]. - The net cash flow from financing activities was -¥24,707,122.79, compared to -¥41,753,386.60 in Q1 2021, showing an improvement of about 40.8%[39]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,558,066,805.79, reflecting a 1.38% increase from CNY 3,509,475,704.32 at the end of the previous year[5]. - The total current assets are ¥1,853,630,283.44, an increase from ¥1,794,398,329.56 at the beginning of the year[28]. - The total current liabilities are ¥594,983,958.51, an increase from ¥567,891,147.96 at the beginning of the year[29]. - The total liabilities decreased to CNY 706,370,108.51 from CNY 731,099,383.73, a decline of 3.4%[30]. - The total equity attributable to shareholders increased to CNY 2,805,908,201.84, a rise of 2.65% from CNY 2,733,520,373.23 at the end of the previous year[5]. Research and Development - Research and development expenses increased by 52.97% to CNY 1,591.64 million compared to CNY 1,040.52 million in the previous year[19]. - Research and development expenses increased to CNY 15,916,371.28 from CNY 10,405,242.10, marking a rise of 53.3%[33]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 61,314[24]. - The top shareholder, Yongjin Investment Holdings Co., Ltd., holds 6.96% of shares, totaling 50,100,000 shares[24]. Other Financial Metrics - The company's weighted average return on equity was 2.68%, up from 2.04% in the same period last year[5]. - The company reported a decrease in management expenses by 32.89% to CNY 2,861.09 million compared to CNY 4,263.22 million in the previous year[19]. - Other comprehensive income after tax was CNY -3,102,758.42, compared to CNY 4,274,940.08 in the previous year[34]. - The company reported a decrease in government subsidies recognized during the reporting period compared to the same period last year[23]. - The company experienced a reduction in credit impairment losses due to changes in accounts receivable balance and aging[23].

Financial Performance - The company reported a total share capital of 720,146,333 shares, with a cash dividend of RMB 0.50 per 10 shares for all shareholders [7]. - The company has not experienced significant performance declines or losses, indicating stable financial health [5]. - The company's operating revenue for 2021 was ¥1,268,579,510.95, representing a 19.50% increase compared to ¥1,061,574,380.03 in 2020 [21]. - The net profit attributable to shareholders in 2021 was ¥161,773,106.85, a significant turnaround from a loss of ¥126,536,626.06 in 2020, marking a 227.85% increase [21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥80,679,566.77, up 149.67% from a loss of ¥162,423,497.06 in 2020 [21]. - The net cash flow from operating activities increased by 32.72% to ¥378,155,561.13 in 2021, compared to ¥284,922,007.78 in 2020 [21]. - The total assets at the end of 2021 were ¥3,509,475,704.32, a decrease of 4.65% from ¥3,680,801,103.97 at the end of 2020 [21]. - The net assets attributable to shareholders increased by 3.42% to ¥2,733,520,373.23 at the end of 2021, compared to ¥2,643,042,773.40 at the end of 2020 [21]. - The company reported a basic earnings per share of ¥0.2241 in 2021, a recovery from a loss of ¥0.1750 in 2020, reflecting a 228.06% increase [21]. - The company’s weighted average return on equity improved to 6.00% in 2021, compared to -4.77% in 2020 [21]. Corporate Governance and Compliance - The board of directors has confirmed the accuracy and completeness of the annual report, ensuring no misleading statements or omissions [4]. - The company maintains a commitment to corporate governance and social responsibility, as outlined in the report [9]. - The company is subject to special industry disclosure requirements due to its operations in the medical device sector [6]. - The company has established a dedicated investor relations team to facilitate communication with stakeholders [19]. - The company emphasizes strict quality control, investing significantly in quality management teams and training to maintain high product standards [48][49]. - The company is committed to ensuring the accuracy of its financial reporting and maintaining transparency with stakeholders [69][70]. Research and Development - The company is actively involved in research and development of minimally invasive surgical products, enhancing its product offerings [15]. - The company is focusing on developing minimally invasive orthopedic products, particularly through its dual-brand strategy with Aideer [36]. - The company is actively investing in research and development to enhance product offerings and improve surgical outcomes [60]. - R&D investment totaled CNY 74.25 million, an increase of CNY 18.35 million or 32.82% year-on-year, accounting for 5.85% of revenue, up 0.58 percentage points [103]. - The company is focusing on research and development to improve existing products and create new solutions for orthopedic applications [84]. - The company is committed to ongoing research and development to enhance its product portfolio and maintain market relevance [63][66]. Market Strategy and Expansion - The company is actively expanding its distribution channels and partnerships with major hospitals to enhance its market share in the medical device sector [41]. - The company has successfully penetrated the local hospital market, expanding its customer base beyond tier-three hospitals [43]. - The company aims to enhance profitability by controlling costs and improving operational efficiency in response to potential negative impacts from centralized procurement policies [34]. - The company plans to closely monitor the centralized procurement process and adjust its business strategies accordingly to mitigate the impact of these policies [33]. - The company is focusing on expanding its product offerings in the orthopedic market, as evidenced by the variety of plates listed in the procurement results [56][57][58]. - The company aims to strengthen its competitive position through strategic partnerships and potential acquisitions in the orthopedic sector [60]. - The company is exploring potential mergers and acquisitions to enhance its technological capabilities and market reach [69][70]. Product Development and Innovation - The company has expanded its product line from a single spinal product to a comprehensive range of orthopedic high-value consumables, including trauma, spine, and minimally invasive joint products [36]. - The company has established a joint venture with TECRES S.P.A to develop advanced bone cement products, enhancing its product offerings in the orthopedic sector [37]. - The company has optimized its sales model and marketing system in response to orthopedic centralized procurement policies, improving its core competitiveness [38]. - The company is focusing on expanding its product offerings in the locking plate category, with multiple new designs launched in 2021 [72]. - The company is actively pursuing technological advancements in its product designs, as evidenced by the variety of locking plates introduced [62]. - The company is likely to benefit from the growing demand for advanced orthopedic solutions, as indicated by the variety of products offered [88]. Financial Challenges and Risks - The company faced significant price reductions in orthopedic consumables due to centralized procurement policies, with average price drops reaching up to 89.45% for certain products [33]. - The company has recognized a goodwill impairment provision of CNY 149.26 million due to significant price reductions in orthopedic trauma products following centralized procurement initiatives [189]. - The company is likely to explore further market expansion opportunities given the introduction of new product lines in the orthopedic sector [72]. - The company has implemented strict accounts receivable management to mitigate risks associated with large receivables and potential collection issues [192]. - The company is facing risks from centralized procurement policies that could impact sales if it fails to win bids in certain regions [187]. Operational Performance - The company achieved operating revenue of 1,268.58 million yuan, an increase of 19.50% compared to the previous year [97]. - The overall operating performance showed significant growth, driven by the recovery in outpatient and surgical volumes post-pandemic [98]. - The company has established a comprehensive platform focusing on high-value medical devices, particularly in the orthopedic field [106]. - The company’s revenue from the East China market reached CNY 542.41 million, a significant increase of 86.74% year-on-year [112]. - The company reported a significant increase in other manufacturing expenses by 33.91% year-on-year, totaling ¥31,647,105.37 [118]. Acquisitions and Investments - The company plans to acquire 100% equity of Elliquence, LLC for USD 77.15 million (approximately CNY 49.50 million) to enhance its international strategy [143]. - The company completed the payment for the acquisition of Elliquence, LLC, with the total transaction price settled as per the agreement [143]. - The company completed the acquisition of 51% of Guoyao Jieno Medical Services Co., entering the third-party disinfection center medical service field, and plans to expand capital through industry investment funds [170]. - The company has completed a capital increase of CNY 12 million in Dongzhi Medical, raising its stake to 24.13% [106]. - The company holds a 55% equity stake in Aideer, with a book value of CNY 404,564,765 as collateral for loans [147]. Regulatory and Compliance Issues - The company has obtained all necessary licenses for medical device production and operations, with a low likelihood of failing to renew these licenses in the future [183]. - The company has not faced any product liability claims or related legal issues since its establishment, thanks to a robust quality control system [184]. - The company is committed to enhancing its governance structure and compliance with regulatory requirements to promote healthy development [197]. - The company held 1 annual general meeting and 4 extraordinary general meetings during the reporting period [199]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements [200].

上海凯利泰医疗科技股份有限公司 2021 年第三季度报告 上海凯利泰医疗科技股份有限公司 二○二一年第三季度报告 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 股票代码：300326 股票简称：凯利泰 披露日期：二○二一年十月二十八日 1 上海凯利泰医疗科技股份有限公司 2021 年第三季度报告 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2 上海凯利泰医疗科技股份有限公司 2021 年第三季度报告 截止披露前一交易日的公司总股本： 4.审计师发表非标意见的事项 □ 适用 √ 不适用 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, with total revenue reaching RMB 200 million, representing a year-on-year growth of 25%[13]. - The company's operating revenue for the reporting period was ¥635,674,828.80, representing a 30.87% increase compared to ¥485,733,168.00 in the same period last year[20]. - The net profit attributable to shareholders decreased by 4.77% to ¥113,702,989.39 from ¥119,394,887.61 year-on-year[20]. - The net profit after deducting non-recurring gains and losses was ¥104,045,383.63, a slight decrease of 0.67% compared to ¥104,745,366.27 in the previous year[20]. - The net cash flow from operating activities was ¥109,081,738.70, down 19.32% from ¥135,204,250.77 in the same period last year[20]. - The total assets at the end of the reporting period were ¥3,627,804,582.91, a decrease of 1.44% from ¥3,680,801,103.97 at the end of the previous year[20]. - The net assets attributable to shareholders increased by 4.60% to ¥2,764,684,456.92 from ¥2,643,042,773.40 at the end of the previous year[20]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2021, representing a year-over-year growth of 25%[46]. - The gross margin for the first half of 2021 improved to 60%, up from 55% in the same period last year, reflecting better cost management and pricing strategies[53]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, targeting new regions in Southeast Asia, which could potentially increase market share by 15%[13]. - The company has provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 25% based on current market trends and product demand[13]. - The company aims to enhance its competitive edge by increasing investment in innovative high-value medical consumables[44]. - The company is focusing on market expansion, targeting an increase in market share by 10% in the orthopedic device sector by the end of 2022[46]. - The company plans to expand its distribution network by adding 50 new sales representatives across key regions in China by the end of 2021[46]. - The company is actively pursuing market expansion strategies, particularly in the EU and Indonesia, to increase its global footprint in the medical device sector[56]. - The company is expanding its market presence in international regions, with plans to enter the Brazilian and Mexican markets by the end of 2021[66]. - The company is focusing on expanding its market presence in Latin America, with plans to enter three new countries by the end of 2022[61]. Product Development and Innovation - New product development includes the launch of a minimally invasive surgical system, which is expected to contribute an additional RMB 50 million in revenue by the end of the year[13]. - New product development includes the launch of 10 innovative medical devices, with expected regulatory approval dates ranging from 2024 to 2026[47]. - The company has developed 150 core patent technologies related to its main business, including 34 invention patents, to enhance its R&D capabilities[39]. - The company aims to launch three new product lines in 2024, including a new generation of spinal implants and orthopedic fixation devices[49]. - The company has introduced new products such as the "Kyphoplasty System" and "Multifunctional Tools" aimed at minimally invasive orthopedic procedures[52]. - The company is expanding its product line with the introduction of Bipolar Radio Frequency Electrodes, which are designed for soft tissue cutting and coagulation[71]. - New product development includes the launch of the Meddusa Bipolar System, which is expected to enhance surgical efficiency and is set for FDA approval in 2024[74]. Research and Development - Research and development expenses have increased by 10% to RMB 20 million, focusing on innovative medical devices and technologies[13]. - The company is investing 100 million RMB in R&D for new technologies aimed at improving surgical outcomes and patient safety[46]. - Research and development investments have increased by 30% compared to the previous year, focusing on innovative medical devices and technologies[53]. - The R&D budget has been increased by 10% to support innovation in medical technology, with a focus on high-frequency surgical devices[70]. - The company is committed to innovation in surgical technology, with ongoing research and development efforts aimed at enhancing the efficacy of its medical devices[64]. Acquisitions and Partnerships - The company has completed a strategic acquisition of a local medical technology firm, enhancing its product portfolio and expected to generate an additional RMB 30 million in annual revenue[13]. - The company has completed a strategic acquisition of a smaller competitor, which is expected to enhance its product portfolio and increase market penetration by 5%[46]. - The company completed the acquisition of 100% equity in Elliquence, LLC, leveraging its existing resources in spinal minimally invasive products to accelerate market entry in China[81]. - The company has established partnerships with key healthcare providers to enhance distribution channels and improve market penetration[62]. - The company is exploring potential acquisitions to bolster its product portfolio, with a focus on companies specializing in innovative surgical technologies[49]. Regulatory and Compliance - The company has identified potential risks related to regulatory changes in the medical device industry, which may impact future operations[4]. - The company is currently applying for 11 domestic medical device product registration certificates, including 7 Class III and 4 Class II certificates[51]. - The company is focused on maintaining compliance with international standards, as evidenced by its efforts to secure CE Mark certification for its products in the European Union[64]. - The regulatory landscape for the company's products is being actively managed, with a focus on compliance and timely submissions to relevant authorities[76]. Financial Position and Cash Flow - The company has maintained a strong cash position, with cash reserves of RMB 100 million, providing flexibility for future investments and acquisitions[13]. - The company's cash and cash equivalents decreased by 1.04% to ¥647.02 million from ¥694.81 million at the end of the previous year[99]. - The total liabilities decreased to CNY 813,665,209.71 from CNY 993,482,147.96, showing a reduction of about 18.1%[200]. - The company's non-current assets remained relatively stable at CNY 1,858,564,971.78 compared to CNY 1,858,946,507.42 at the end of 2020[199]. Market Challenges and Risks - The company has been impacted by the COVID-19 pandemic, which has affected its financial performance and operational results[136]. - Regulatory changes in the medical device sector may lead to price reductions, posing challenges to the company's market competitiveness[144]. - The internationalization strategy may expose the company to unfamiliar overseas market conditions and increased operational management demands[148].

上海凯利泰医疗科技股份有限公司 2021 年第一季度报告 上海凯利泰医疗科技股份有限公司 二 0 二一年第一季度报告 证券代码：300326 股票简称：凯利泰 披露日期：二○二一年四月二十六日 1 上海凯利泰医疗科技股份有限公司 2021 年第一季度报告 第一节 重要提示 1、公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或者重大遗漏，并承担个别和连带的法律责任。 2、所有董事均已出席了审议本次季报的董事会会议。 3、公司负责人袁征、主管会计工作负责人李元平及会计机构负责人(会计主管人员)李元平声明：保证季度报告中财务报表 的真实、准确、完整。 4、公司第一季度财务报告未经会计师事务所审计。 非标准审计意见提示 □ 适用 √ 不适用 2 上海凯利泰医疗科技股份有限公司 2021 年第一季度报告 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 305,6 ...

Financial Performance - In 2020, the company achieved operating revenue of CNY 1,061.57 million, a decrease of 13.15% compared to the previous year[5]. - The net profit attributable to shareholders was a loss of CNY 126.54 million, representing a decline of 141.85% year-on-year[5]. - The significant loss was primarily due to reduced outpatient and surgical volumes in hospitals caused by the COVID-19 pandemic, leading to a decline in sales revenue[5]. - The company recognized an impairment loss of CNY 365.59 million related to goodwill for its subsidiary Ningbo Shen Ce, impacting the net profit for the year[5]. - The company's operating revenue for 2020 was ¥1,061,574,380.03, a decrease of 13.15% compared to ¥1,222,288,041.86 in 2019[17]. - The net profit attributable to shareholders was -¥126,536,626.06 in 2020, representing a decline of 141.85% from ¥302,327,376.55 in 2019[17]. - The weighted average return on net assets was -4.77% in 2020, a decrease of 16.26% from 11.49% in 2019[17]. - The company reported a basic earnings per share of -¥0.1750 for 2020, down 141.78% from ¥0.4189 in 2019[17]. Dividend and Shareholder Returns - The company plans to implement a cash dividend of CNY 0.5 per 10 shares, with no bonus shares or capital reserve transfers proposed[7]. - The total number of shares for the dividend distribution is based on 722,962,682 shares after excluding treasury shares[7]. - In 2020, the company distributed cash dividends of RMB 0.50 per share, totaling RMB 36,148,134.10, based on a total share count of 722,962,682 shares[200]. - The company implemented a stable profit distribution policy, ensuring that cash dividends account for at least 10% of the distributable profits each year[199]. Market and Product Strategy - The company plans to focus on the development of orthopedic minimally invasive products and expand into general surgery minimally invasive high-value consumables[26]. - The company aims to achieve rapid growth in orthopedic product sales by leveraging its accumulated orthopedic channel resources[26]. - The company has successfully expanded its product line from a single spinal product to a comprehensive range covering orthopedic trauma, spinal, and minimally invasive joint products[26]. - The company aims to expand its product line in the orthopedic field through strategic partnerships and technological advancements[28]. - The company is focusing on optimizing its sales model and enhancing its marketing system to ensure sustainable growth in core business[30]. - The company aims to enhance its market presence through the introduction of innovative medical devices and potential acquisitions in the healthcare sector[47][48]. - The company is actively involved in the development of new technologies and products to enhance its market position in the medical device sector[47][48]. Acquisitions and Investments - The company acquired 100% of Elliquence, LLC for 168.15 million yuan, enhancing its capabilities in high-value consumables and surgical energy platforms[31]. - The company has established a joint venture with Sinopharm Holdings to create a high-standard regional medical device distribution platform, enhancing its market presence[32]. - The company plans to acquire 100% equity of Elliquence, LLC for $77.152 million (approximately RMB 495 million), with an initial payment of $61.552 million completed and the remaining $15.6 million to be paid in installments over the next three years[36]. - The company acquired a 16.67% stake in Shanghai Jiguan Medical Technology Co., Ltd. for RMB 24.1129 million, which specializes in spinal resistance measurement probes, enhancing the standardization and simplification of PKP surgeries[39]. - The company completed the acquisition of Shanghai Yidong Medical Technology Co., Ltd. for a total consideration of 58.76 million, representing a 26.10% ownership stake[126]. - The company completed the acquisition of 100% equity in Aideer, with a registered capital of 110 million CNY, and a net profit contribution of 5,786,000 CNY from Aideer in the reporting period[156][158]. Research and Development - R&D investment totaled ¥55,906,500, accounting for 5.27% of revenue, an increase of 0.69 percentage points from the previous year[81]. - The company aims to strengthen its R&D focus on orthopedic minimally invasive surgical products to maintain a competitive edge in the market[81]. - The company is committed to ongoing research and development to improve surgical outcomes and expand its market presence in the medical technology sector[69]. - The company has established a complete orthopedic industry chain, covering trauma, spine, minimally invasive, and radiofrequency ablation products[169]. - The company is actively researching and developing new technologies to improve its product offerings and maintain competitive advantage[196]. Regulatory Compliance and Quality Control - The company emphasizes the importance of accurate financial reporting and internal controls, with no significant deficiencies reported[5]. - The company maintains a rigorous quality control system, ensuring product quality across all stages from R&D to after-sales service[44][45]. - The company is committed to maintaining compliance with regulatory standards for its medical devices, ensuring safety and efficacy in clinical applications[47][48]. - The company has obtained all necessary licenses for production and operation, with a low likelihood of failing to renew them in the future[184]. - The company has not faced any product liability claims or related legal issues since its establishment, indicating strong product quality control[185]. Challenges and Risks - The significant loss was primarily due to reduced outpatient and surgical volumes in hospitals caused by the COVID-19 pandemic, leading to a decline in sales revenue[5]. - The company is actively monitoring the impact of the COVID-19 pandemic on its operations and financial performance, acknowledging potential adverse effects[183]. - The medical device industry is facing challenges from government policies aimed at cost control, which may limit the growth of medical device expenses in healthcare institutions[167]. - The company anticipates increased market competition in the minimally invasive intervention sector, particularly in vertebroplasty products, due to low market concentration in China[181]. - The company faces management risks related to its internationalization strategy, including unfamiliarity with overseas markets and differing customer needs[194]. Future Outlook - The company has outlined a future outlook with a projected revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[49]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[49]. - Future development plans include expanding the market presence of the Elliquence product line, which is expected to have significant market potential[196]. - The company aims to leverage its research and development capabilities to introduce new technologies that address unmet medical needs in spine surgery[60]. - The company is exploring opportunities for market expansion and potential mergers and acquisitions to drive growth[196].

Financial Performance - Net profit attributable to shareholders was ¥76,798,750.11, reflecting a year-on-year increase of 12.87%[7] - Operating income for the period was ¥306,443,501.48, representing a growth of 5.12% compared to the same period last year[7] - Basic earnings per share rose to ¥0.1063, an increase of 12.85% year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥68,538,012.29, up by 6.54% year-on-year[7] - The company reported a net profit of CNY 1,346,021,187.24, up from CNY 1,185,975,683.62, indicating a growth of about 13.5% in retained earnings[65] - Net profit for Q3 2020 reached CNY 79,091,678.39, up from CNY 68,011,187.10 year-over-year, indicating a growth of approximately 16.5%[72] - The net profit for Q3 2020 was ¥99,091,967.80, down 24.5% from ¥131,353,440.19 in Q3 2019[85] Cash Flow - The net cash flow from operating activities increased significantly by 74.07% to ¥51,480,923.63[7] - The net cash flow from operating activities was 186.69 million yuan, an increase of 123.58% year-on-year, attributed to good accounts receivable collection despite a decline in revenue due to the COVID-19 pandemic[38] - The cash flow from operating activities increased to ¥186,685,174.40, compared to ¥63,102,196.67 in the previous year, marking a significant improvement[87] - The company experienced a net cash outflow from financing activities of -¥23,830,134.76, compared to -¥198,583,487.93 in the same period last year[88] - The total cash inflow from investment activities was ¥594,663,495.98, while cash outflow was ¥800,350,749.15, resulting in a net cash flow of -¥205,687,253.17 from investment activities[88] Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,969,002,101, an increase of 5.27% compared to the end of the previous year[7] - The company reported a total of 722,976,333 shares outstanding as of the last trading day before the report was disclosed[7] - Total liabilities decreased to CNY 979,010,735.79 from CNY 1,018,114,106.83, a reduction of approximately 3.8%[64] - The company's total equity increased to CNY 2,744,353,480.53 from CNY 2,654,927,428.88, reflecting a growth of approximately 3.4%[68] - The total liabilities of the company were recorded at ¥900,312,407.92, with current liabilities at ¥659,336,167.92[95] Shareholder Information - The top ten shareholders held a combined 43.98% of the company's shares, with the largest shareholder holding 6.93%[11] - The company repurchased a total of 8,513,651 shares, accounting for 1.178% of the total share capital, with a total payment of approximately RMB 86.96 million[50] - The maximum transaction price during the repurchase was RMB 10.77 per share, while the minimum was RMB 9.34 per share[50] Investments and Acquisitions - The company plans to acquire 51% of the equity of Guoyao Jienuo Medical Services Co., Ltd. for no less than 100.88 million yuan through the Shanghai United Assets and Equity Exchange[48] - The company has completed a capital increase of 60 million yuan in Shanghai Lige Tai Biotechnology Co., Ltd., holding 11.215% of its equity[47] Operational Insights - The company expects continued recovery in surgical volumes and business performance following the control of the COVID-19 pandemic[19] - The company is actively monitoring the impact of the pandemic on its various business segments[57] - The company is focusing on the market prospects of its main products, including PKP and PVP, and their penetration rates in the domestic market[57] - The company is planning to strengthen its relationships with hospitals to enhance product stickiness[57] Research and Development - Research and development expenses for Q3 2020 were CNY 11,132,483.64, slightly down from CNY 12,169,333.53 in the previous year[71] - Research and development expenses for Q3 2020 were ¥19,468,775.02, slightly down from ¥21,074,074.45 in the same period last year[83] Other Financial Metrics - The weighted average return on equity was 2.60%, a decrease of 0.34% compared to the previous year[7] - Financial expenses decreased by 6.38 million yuan, a reduction of 41.48% year-on-year, mainly due to lower interest expenses[31] - Other income increased by 111.14 million yuan, a growth of 148.86% year-on-year, primarily due to an increase in government subsidies recognized during the reporting period[32]

Financial Performance - The company reported a revenue of RMB 100 million for the first half of 2020, representing a year-on-year increase of 15%[13]. - The net profit attributable to shareholders for the same period was RMB 20 million, up 10% compared to the previous year[13]. - The company's operating revenue for the first half of 2020 was ¥485,733,168, a decrease of 14.54% compared to ¥568,398,441 in the same period last year[17]. - Net profit attributable to shareholders was ¥119,394,888, down 22.37% from ¥153,792,625 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was ¥104,745,366, reflecting a 27.94% decrease from ¥145,368,254 in the same period last year[17]. - The gross margin for the first half of 2020 was reported at 60%, reflecting improved operational efficiency and cost management strategies[47]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2020, representing a year-over-year growth of 25%[57]. - The company has provided a positive outlook for the second half of 2020, projecting a revenue growth of 20% to 30% based on current market trends and demand[47]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2021[13]. - The company plans to continue investing in sports medicine, having received multiple product approvals, including a Class III medical device registration for a suture anchor used in soft tissue repair surgeries[31]. - The company is expanding its market presence by entering three new provinces in China, aiming to increase its market share by 10% in these regions by the end of 2021[47]. - The company has established a joint venture with China National Pharmaceutical Group to create a regional medical device distribution platform, enhancing its market presence and distribution capabilities[32]. - The company is actively pursuing international markets, with registration applications in countries such as Argentina and Australia for various medical devices[52]. - The company is focused on long-term development and market expansion in regions like Brazil and Colombia[53]. - The company is exploring potential acquisitions to bolster its technology capabilities and expand its product offerings[50]. Research and Development - The company has allocated RMB 5 million for research and development in low-temperature plasma radiofrequency ablation products[13]. - Research and development investments have increased by 30% year-over-year, focusing on advanced surgical technologies and minimally invasive procedures[47]. - The total R&D investment for the reporting period was 20.32 million yuan, a decrease of 8.48% year-on-year, with R&D investment accounting for 4.18% of revenue, an increase of 0.28 percentage points year-on-year[77]. - The company has obtained 10 authorized patents during the reporting period, emphasizing its commitment to intellectual property management[77]. - The company is committed to innovation in medical technology, as evidenced by its ongoing development of high-frequency surgical devices[63]. Product Development and Launches - New product development includes a minimally invasive surgical system, expected to launch in Q4 2020, with projected sales of RMB 30 million in the first year[13]. - New product launches include a spinal fixation system and a dual-frequency surgical knife, expected to contribute an additional $10 million in revenue in 2024[50]. - The company has introduced a competitive compensation system to attract high-level talent, which is expected to enhance its core competitiveness in R&D, quality, and market sales[41]. - The company has established partnerships with five leading hospitals to enhance product testing and user feedback, aiming to improve product efficacy and user satisfaction[48]. - The company has reported a significant expansion in its product offerings, including the introduction of the Disc-FX system for intervertebral disc removal procedures, which is expected to enhance surgical outcomes[60]. Risk Management and Compliance - The board of directors has emphasized the importance of risk management strategies in response to market uncertainties[6]. - The financial report for the first half of 2020 has not been audited, and investors are advised to consider potential risks[6]. - The company maintains a strict quality control system, viewing product quality as vital, and has established a comprehensive quality management framework[43]. - The company has not faced any significant litigation or arbitration matters during the reporting period, indicating a stable legal environment[161]. - The company has committed to avoiding related party transactions and competition issues as part of its operational strategy[159]. Shareholder and Equity Management - The company does not plan to distribute cash dividends or issue bonus shares for the current fiscal year[7]. - The company has implemented a stock incentive plan, resulting in an increase of 16.74 million yuan in share-based payment expenses compared to the previous year[72]. - The company approved the 2019 restricted stock incentive plan, granting 8.5 million shares at a price of 4.94 CNY per share to 24 incentive recipients[165]. - The company has repurchased a total of 8,513,651 shares, accounting for 1.178% of the total share capital, with a total expenditure of RMB 86,959,460.42[182]. - The company plans to use its own funds or raised funds for share repurchase, with a total amount not less than RMB 80 million and not exceeding RMB 150 million[182].